Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-Dose Therapy+ASCT in Multiple Myeloma Studied

JAMA Oncol; ePub 2018 Jan 4; Dhakal, Szabo, et al

High-dose therapy with melphalan+autologous stem cell transplant (HDT/ASCT) resulted in better progression-free survival than standard dose therapy (SDT) in patients with multiple myeloma, according to a meta-analysis of 9 studies involving nearly 6,000 individuals. Investigators included studies comparing single HDT/ASCT with SDT using novel agents. They looked at progression-free and overall survival, complete response, and treatment-related mortality. Among the findings:

  • Patients receiving HDT/ASCT were 27% more likely to experience complete response than those receiving SDT.
  • HDT patients experienced better progression-free and overall survival.
  • Patients receiving tandem HDT/ASCT experienced the most favorable progression-free survival, followed by single HDT/ASCT with bortezomib, lenalidomide, and dexamethasone; and single HDT/ASCT alone.
  • No HDT/ASCT-based approach significantly impacted overall survival.
  • HDT/ASCT treatment-related mortality was minimal.

Citation:

Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis. [Published online ahead of print January 4, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4600.

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018

Must Reads in Myelodysplastic Syndrome

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126 https://doi.org/10.1016/S2352-3026(18)30016-4

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al